TX-SNOW-SOFTWARE
16.11.2023 15:01:58 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today previewed Snow Copilot, the first-in-a-series of Artificial Intelligence (AI) capabilities designed to solve large challenges in IT Asset Management (ITAM) and FinOps. Developed in its innovation incubator Snow Labs, Snow Copilot is an AI assistant that empowers users to ask conversational questions and receive natural language responses. At release, Snow Copilot is available for Software Asset Management (SAM) computer data in Snow Atlas with more use cases being explored over time.
Snow Labs is a multiprong innovation initiative to help organizations make better decisions and deliver positive business outcomes with Technology Intelligence, or the ability to understand and manage all technology data, via Snow Atlas. The current project focuses on using artificial intelligence to advance data insights and further explore ways to tackle multifaceted ITAM and FinOps challenges, the first offering powered by Snow AI.
“We created Snow Labs as a space for rapid experimentation and prototyping, allowing us to test emerging technologies that sat outside of our standard product roadmap,” said Steve Tait, Chief Technology Officer and EVP, Research and Development at Snow. “Artificial intelligence is a great example of a rapidly evolving, emerging technology that could allow Snow Labs to address a myriad of challenges our customers face when making sense of their technology asset data. We believe that AI will fundamentally transform the way our customers and partners interact with their data. This is just one of many ways we are working to bring our vision around Technology Intelligence to life through innovation.”
Enhancing the Value of Data with Snow
IT manages vast amounts of data but struggles to turn that data into actionable intelligence for business impact. According to a recent Snow report, 91% of IT leaders said they need to invest in tools to extract more value out of their data. This is a contributing factor in the growing visibility gap between IT and the business units they support. IT struggles to know what software and cloud services are running both within IT and across the enterprise leading to technology overspend, higher security and compliance risk, reduced ITSM data quality, and slower decision-making. Generative AI provides new toolsets for Snow to tackle the visibility gap when it comes to understanding and acting on large technology asset data sets for ITAM, SaaS management, and FinOps.
Snow Copilot, one of the first AI assistants developed to solve advanced challenges for ITAM and FinOps, leverages the Microsoft Azure OpenAI Service. It allows customers to input questions and receive insights on their computer data, such as “How many computers have been installed in the last 90 days?,” as well as explore “what if” scenarios all directly within Snow Atlas. Snow Copilot reduces the need to export data into PowerBI or Excel to get insights into advanced questions on forecasting, asset allocation, and trend identification of SAM computer data. All data remains secure in the customer environment ensuring data privacy and integrity.
Additional AI-enabled features within the Snow AI umbrella are under exploration for 2024, including:
- Machine Learning Entitlement Ingestion: Eliminate manual, costly entitlement uploads with automated invoice processing powered by machine learning.
- Enhanced Data Intelligence Service (DIS) dataset with OpenAI: Receive more context about the SaaS applications running in your organization with enhanced descriptions including richer details on categories, function, etc. from the Snow DIS normalization and augmentation service.
- Fine-tuning Large Language Models (LLM) on Snow proprietary data: Make more informed and complex decisions on technology assets with personalized licensing recommendations.
These new AI capabilities will be available on Snow Atlas, the company’s Technology Intelligence platform. The platform, released in 2021, provides a more flexible and scalable foundation for continuous innovation. Snow Atlas allows organizations to bring together their ITAM, SaaS management, cloud cost and FinOps functions, providing a unified view and actionable intelligence to manage the entire IT landscape.
“The pace at which we can innovate on Snow Atlas, both in our standard product development cycles and through Snow Labs, is remarkable with more than one production release every day for the last three quarters,” said Tait. “We are entering a new era which will redefine how we work with technology, and we want to ensure organizations feel confident and prepared to embrace this monumental shift.”
Snow Copilot and other AI innovations will be available for current Snow Atlas customers who apply for the beta program. To learn more about Snow Labs and its innovation agenda, read CTO Steve Tait’s latest blog or to discover more on Snow Atlas, visit: https://www.snowsoftware.com/products/snow-atlas/.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116093425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
